Publications dans lesquelles il/elle collabore avec Monica Cabrero Calvo (18)

2024

  1. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

    Bone Marrow Transplantation, Vol. 59, Núm. 3, pp. 359-365

  2. Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells

    Cytotherapy, Vol. 26, Núm. 8, pp. 806-812

2022

  1. ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S369-S370

  2. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

    Cancers, Vol. 14, Núm. 22

  3. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438

2021

  1. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  2. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

    Bone Marrow Transplantation

2020

  1. Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic

    Frontiers in Medicine, Vol. 7

2019

  1. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2017

  1. 18F-FDG PET/CT in the clinical management of patients with lymphoma

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 36, Núm. 5, pp. 312-321

  2. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2016

  1. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815

  2. The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: A pilot trial from the GETH and GELLC (CLL4 trial)

    Bone Marrow Transplantation

2015

  1. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

  2. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

2013

  1. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate

    Haematologica, Vol. 98, Núm. 4, pp. 526-532

2012

  1. Update on the role of autologous hematopoietic stem cell transplantation in follicular lymphoma

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 4, Núm. 1